.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX25_Mosunetuzumab.Mosunetuzumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX25_Mosunetuzumab.Mosunetuzumab| name: | Mosunetuzumab |
| ATC code: | L01FX25 | route: | intravenous |
| n-compartments | 2 |
Mosunetuzumab is a bispecific CD20-directed CD3 T-cell engager monoclonal antibody that is used for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. It was approved by the FDA in December 2022.
Population pharmacokinetics in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Munakata, W, et al., & Ishizawa, K (2023). Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Japanese journal of clinical oncology 53(10) 912–921. DOI:10.1093/jjco/hyad082 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37486002
Li, J, et al., & Turner, DC (2025). Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma. Clinical and translational science 18(5) e70211–None. DOI:10.1111/cts.70211 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40279333
Li, CC, et al., & Wei, MC (2025). A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma. Clinical pharmacology and therapeutics 117(2) 465–474. DOI:10.1002/cpt.3445 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39328022